Rocket Pharmaceuticals Inc (RCKT)

Feb 27, 2025, 4:01 PM EST - 4 weeks ago

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Feb 12, 2025, 3:40 PM EST - 7 weeks ago

Rocket Pharma Is A Buy At These Prices With Promising Data

Jan 6, 2025, 7:19 AM EST - 3 months ago

Top 3 Health Care Stocks That Could Blast Off This Month

INO OTLK

Jan 2, 2025, 4:00 PM EST - 3 months ago

Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 3:00 PM EST - 3 months ago

Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'

Dec 11, 2024, 7:00 AM EST - 4 months ago

Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Dec 10, 2024, 4:01 PM EST - 4 months ago

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

Nov 26, 2024, 7:00 AM EST - 4 months ago

Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference

Nov 19, 2024, 2:47 PM EST - 4 months ago

Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst

Nov 18, 2024, 11:00 AM EST - 4 months ago

Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference

Nov 12, 2024, 4:01 PM EST - 5 months ago

Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science Sessions

Nov 8, 2024, 7:00 AM EST - 5 months ago

Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference

Nov 7, 2024, 4:01 PM EST - 5 months ago

Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

Sep 19, 2024, 3:18 PM EDT - 6 months ago

Rocket: Danon Disease Treatment Program Should Carry The Tide Until Regulatory Moves

Sep 17, 2024, 7:00 AM EDT - 7 months ago

Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease

Sep 10, 2024, 7:00 AM EDT - 7 months ago

Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors

Aug 27, 2024, 7:00 AM EDT - 7 months ago

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 5, 2024, 4:01 PM EDT - 8 months ago

Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress

Jul 29, 2024, 3:32 PM EDT - 8 months ago

3 Biotech Names With Potential Catalysts By Year End

CADL VRDN

Jun 28, 2024, 1:26 PM EDT - 9 months ago

FDA Again Delays Approval of Rocket Pharmaceuticals' Gene Therapy Treatment

Jun 28, 2024, 7:27 AM EDT - 9 months ago

Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)

May 29, 2024, 7:00 AM EDT - 11 months ago

Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy

May 10, 2024, 6:00 AM EDT - 11 months ago

Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

May 6, 2024, 4:01 PM EDT - 11 months ago

Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress

Apr 5, 2024, 11:50 AM EDT - 1 year ago

Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)

Apr 2, 2024, 2:34 PM EDT - 1 year ago

Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch

Apr 2, 2024, 6:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

Mar 26, 2024, 4:01 PM EDT - 1 year ago

Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team

Mar 1, 2024, 6:03 PM EST - 1 year ago

Rocket Pharmaceuticals' Promising Path In Gene Therapy

Feb 26, 2024, 4:01 PM EST - 1 year ago

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

Feb 13, 2024, 7:00 AM EST - 1 year ago

Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Jan 2, 2024, 4:01 PM EST - 1 year ago

Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 14, 2023, 1:24 PM EST - 1 year ago

Best Small-Cap Stocks to Buy for 2024 and Beyond

ARVN ASO BOOT FLYW GH IMVT PRVA

Dec 12, 2023, 7:00 AM EST - 1 year ago

Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors

Nov 6, 2023, 4:04 PM EST - 1 year ago

Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

Oct 19, 2023, 7:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Oct 2, 2023, 7:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Sep 26, 2023, 4:01 PM EDT - 1 year ago

Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference

Sep 21, 2023, 7:30 AM EDT - 1 year ago

Rocket Pharmaceuticals: Update On RP-A501 Strengthens Bullish Outlook

Sep 14, 2023, 9:40 AM EDT - 1 year ago

Rocket Pharmaceuticals: Soaring On Pivotal Danon Disease Study Agreement - More Upside Ahead?

Sep 13, 2023, 10:54 AM EDT - 1 year ago

Rocket Pharmaceuticals Stock Jumps Most Since 2020. New Gene Therapy Is Potential 'Value Driver.

Sep 13, 2023, 12:01 AM EDT - 1 year ago

Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Sep 12, 2023, 4:01 PM EDT - 1 year ago

Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease

Aug 10, 2023, 7:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress

Aug 3, 2023, 12:42 AM EDT - 1 year ago

Rocket Pharmaceuticals: Thriving Gene Therapy With Multiple Catalysts

Jun 8, 2023, 8:25 AM EDT - 1 year ago

Rocket Pharmaceuticals shares rise on FDA fast-track designation for heart disease treatment

Jun 8, 2023, 7:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

May 31, 2023, 7:00 AM EDT - 2 years ago

Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease

May 23, 2023, 7:00 AM EDT - 2 years ago

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD)

May 19, 2023, 6:00 AM EDT - 2 years ago

Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)